Press Releases

 
Press Releases
  Date Title View
Feb 17, 2017
LEXINGTON, MA -- (Marketwired) -- 02/17/17 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced the closing of its previously announced underwritten public offering. Aldeyra sold 2,555,555 shares of its common stock, includi...
PDF
Feb 14, 2017
LEXINGTON, MA -- (Marketwired) -- 02/14/17 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced the pricing of an underwritten public offering of 2,222,222 shares of its common stock at a price to the public of $4.50 per sha...
PDF
Feb 13, 2017
LEXINGTON, MA -- (Marketwired) -- 02/13/17 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to marke...
PDF
Feb 7, 2017
LEXINGTON, MA -- (Marketwired) -- 02/07/17 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it has enrolled the first patient in a Phase 2b clinical trial of ADX-102 for the treatment of allergic conjunctivitis. ...
PDF
Feb 6, 2017
LEXINGTON, MA -- (Marketwired) -- 02/06/17 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will participate at the 2017 Rare Disease, Biopharma One-on-One D...
PDF
Jan 25, 2017
LEXINGTON, MA -- (Marketwired) -- 01/25/17 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Noninfectious Anterior Uveitis: Enrollment of first-ever vehicle-controlled Phase 3 clinical trial is expected to begin in the second quarter of 2017. Sjögren-Larsson Syndrome...
PDF
Nov 22, 2016
LEXINGTON, MA -- (Marketwired) -- 11/22/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the 28th Annual Piper Jaffray Healthcare Conferen...
PDF
Nov 14, 2016
LEXINGTON, MA -- (Marketwired) -- 11/14/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today reported third quarter 2016 financial results. "We are extremely pleased with the progress we have made this year with our nove...
PDF
Nov 9, 2016
LEXINGTON, MA -- (Marketwired) -- 11/09/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the Stifel 2016 Healthcare Conference on Wednesda...
PDF
Nov 8, 2016
LEXINGTON, MA -- (Marketwired) -- 11/08/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced it will issue financial results for the third quarter ended September 30, 2016 on Monday, November 14, 2016, prior to the market...
PDF
Page: FirstPrevious
2
... NextLast